Your SlideShare is downloading. ×
0
Team 4
Team 4
Team 4
Team 4
Team 4
Team 4
Team 4
Team 4
Team 4
Team 4
Team 4
Team 4
Team 4
Team 4
Team 4
Team 4
Team 4
Team 4
Team 4
Team 4
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×
Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply

Team 4

304

Published on

Published in: Health & Medicine
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
304
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
6
Comments
0
Likes
0
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1. TEAM 4<br />Hussein El shamy, Engyhelaly, Ayaat Ali, EslamEl shahat and MarwanFelafel<br />
  • 2. Where are we now?<br />Novartis is a great company which works hard to help patients.<br />The major targets of Novartis are patients’ health and patients’ trust.<br />Novartis want to cover all patients who have chronic myeloid leukemia ( CML ) in Egypt.<br />Novartis produces 2nd line treatment for ( CML ) which is called Pluto.<br />
  • 3. Executive summary<br />Our aim is to be ranked the second in the market within 5 years.<br />The project is prepared to invest 660,000L.E. and to gain 4,320,000l in the first year with an annual increase in the profit around 10%.<br />
  • 4. SWOT<br />Strengths:<br /><ul><li>Rapid & durable response.
  • 5. Effective & safe.
  • 6. Former experience.
  • 7. No cross intolerence with Mirac.</li></ul>Opportunities:<br /><ul><li>Former trust with the customers.
  • 8. Limited number of competitors.</li></ul>Weaknesses:<br /><ul><li>Hypertensive patients.
  • 9. Possibility of incompliance.</li></ul>Threats:<br /><ul><li>Patient Perception.</li></ul>- Managing response.<br />
  • 10. Where do we want to be?<br />Mission statement<br />
  • 11.
  • 12. Strategy Objectives<br />Objectives<br />Mission <br />Goals<br />
  • 13. Qualitative objectives:<br /><ul><li>Higher product quality
  • 14. Recognition as a leader in the leukemia market
  • 15. Higher levels of customer satisfaction and compliance
  • 16. Creating strong reputation in the market.</li></li></ul><li>Quantitative objectives:<br />
  • 17. Augmenting the market share by: 19%<br />Increasing the number of targeted patients by 304 patients.<br />Increasing sales by 5,472,000 LE<br />Improving the drug ranking against competitors 2nd<br />Developing a good ROI & KPI<br />
  • 18. <ul><li>Product variation
  • 19. Pluto is an innovative product
  • 20. Faster 6-9 months only
  • 21. Two distribution patterns </li></ul>Our target is to make Pluto have 100% of the market share<br /><ul><li>We need to reach 75% of the patients
  • 22. Then we will decrease the price by 15%.
  • 23. Medical rep. (4 and 1 DM)
  • 24. Sessions in conferences
  • 25. Local congresses</li></li></ul><li>Discussion panels Seminars organized by the company<br />E-mail and Phone team<br />Governmental sector<br />Direct marketing i.e. Med. Rep<br />Printed Fliers and Brochures<br />Sessions in conferences and Sponsorship<br />
  • 26. How might we get there?<br />
  • 27. Another problem is: Dasatinib<br />But our drug is:<br />MoreSelective <br />With LessAdverse effects<br />AND it is Cheaper!<br />
  • 28. Strategy implementation and evaluation (financial plan)<br />
  • 29. Strategy implementation and evaluation (financial plan)<br />
  • 30.
  • 31. Action Plan<br />
  • 32. How can we ensure our arrival?<br />Key Performance Indicators:<br />
  • 33. Thank You<br />

×